"Psychedelic Drug Firms Paving the Way for Mainstream Acceptance"

Biotech firms are working on developing next-generation psychedelics that aim to either shorten the duration of the psychedelic trip or eliminate the hallucinogenic effects altogether. These advancements are driven by the potential for mainstream adoption of psychedelic drugs, which would require regulatory approval as prescription medicine and could open up the possibility of health insurance coverage. While some believe that shorter trips or non-hallucinogenic psychedelics could make treatment more accessible and efficient, others argue that the mystical experience and longer trips are crucial for therapeutic effects. The development of these new compounds could revolutionize mental health treatment, particularly for conditions such as depression and anxiety.